Open main menu
Home
Random
Recent changes
Special pages
Community portal
Preferences
About Wikipedia
Disclaimers
Incubator escapee wiki
Search
User menu
Talk
Dark mode
Contributions
Create account
Log in
Editing
Protein engineering
(section)
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
==== Multivalent proteins ==== Multivalent proteins are relatively easy to produce by post-translational modifications or multiplying the protein-coding DNA sequence. The main advantage of multivalent and multispecific proteins is that they can increase the effective affinity for a target of a known protein. In the case of an inhomogeneous target using a combination of proteins resulting in multispecific binding can increase specificity, which has high applicability in protein therapeutics. The most common example for multivalent binding are the antibodies, and there is extensive research for bispecific antibodies. Applications of bispecific antibodies cover a broad spectrum that includes diagnosis, imaging, prophylaxis, and therapy.<ref>{{Cite journal|last1=Holliger|first1=P.|last2=Prospero|first2=T.|last3=Winter|first3=G.|date=1993-07-15|title="Diabodies": small bivalent and bispecific antibody fragments.|journal=Proceedings of the National Academy of Sciences|language=en|volume=90|issue=14|pages=6444β6448|doi=10.1073/pnas.90.14.6444|issn=0027-8424|pmc=46948|pmid=8341653|bibcode=1993PNAS...90.6444H |doi-access=free }}</ref><ref>{{Cite journal|last1=Brinkmann|first1=Ulrich|last2=Kontermann|first2=Roland E.|date=2017-02-17|title=The making of bispecific antibodies|journal=mAbs|language=en|volume=9|issue=2|pages=182β212|doi=10.1080/19420862.2016.1268307|issn=1942-0862|pmc=5297537|pmid=28071970}}</ref>
Edit summary
(Briefly describe your changes)
By publishing changes, you agree to the
Terms of Use
, and you irrevocably agree to release your contribution under the
CC BY-SA 4.0 License
and the
GFDL
. You agree that a hyperlink or URL is sufficient attribution under the Creative Commons license.
Cancel
Editing help
(opens in new window)